A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

MLA

Iain R. Macpherson, et al. “A Phase I/II Study of Epertinib plus Trastuzumab with or without Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer.” Breast Cancer Research, vol. 22, no. 1, Dec. 2019, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s13058-019-1178-0.

APA

Iain R. Macpherson, Pavlina Spiliopoulou, Saeed Rafii, Matilde Saggese, Richard D. Baird, Javier Garcia-Corbacho, Antoine Italiano, Jacques Bonneterre, Mario Campone, Nicola Cresti, John Posner, Yousuke Takeda, Akinori Arimura, & James Spicer. (2019). A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22(1), 1–9. https://doi.org/10.1186/s13058-019-1178-0

Chicago

Iain R. Macpherson, Pavlina Spiliopoulou, Saeed Rafii, Matilde Saggese, Richard D. Baird, Javier Garcia-Corbacho, Antoine Italiano, et al. 2019. “A Phase I/II Study of Epertinib plus Trastuzumab with or without Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer.” Breast Cancer Research 22 (1): 1–9. doi:10.1186/s13058-019-1178-0.